Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Buy
52
VMD Quote, Financials, Valuation and Earnings
Last price:
$6.60
Seasonality move
:
23.16%
Day range:
$6.41 - $6.70
52-week range:
$6.21 - $9.81
Dividend yield:
0%
P/E ratio:
23.61x
P/S ratio:
1.20x
P/B ratio:
1.99x
Volume:
122.8K
Avg. volume:
123.2K
1-year change:
-19.88%
Market cap:
$261.2M
Revenue:
$224.3M
EPS (TTM):
$0.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VMD
Viemed Healthcare
|
$63.4M | $0.10 | 19.78% | 25% | $12.83 |
|
AXGN
Axogen
|
$53.4M | $0.08 | 16.84% | -76% | $25.71 |
|
ELMD
Electromed
|
$16.6M | -- | 13.91% | -- | $37.00 |
|
IRIX
IRIDEX
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo
|
$10.9M | -$0.06 | 145.61% | -24% | $9.25 |
|
STXS
Stereotaxis
|
$7.7M | -$0.07 | -0.07% | -20.83% | $4.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VMD
Viemed Healthcare
|
$6.61 | $12.83 | $261.2M | 23.61x | $0.00 | 0% | 1.20x |
|
AXGN
Axogen
|
$15.89 | $25.71 | $704.6M | -- | $0.00 | 0% | 3.75x |
|
ELMD
Electromed
|
$22.53 | $37.00 | $192.8M | 30.04x | $0.00 | 0% | 3.38x |
|
IRIX
IRIDEX
|
$0.94 | -- | $15.7M | -- | $0.00 | 0% | 0.32x |
|
MYO
Myomo
|
$4.43 | $9.25 | $152.3M | -- | $0.00 | 0% | 5.14x |
|
STXS
Stereotaxis
|
$1.66 | $4.50 | $142.7M | -- | $0.00 | 0% | 5.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VMD
Viemed Healthcare
|
2.95% | 0.427 | 1.27% | 1.14x |
|
AXGN
Axogen
|
31.37% | 1.669 | 6.53% | 1.88x |
|
ELMD
Electromed
|
-- | 1.939 | -- | 4.68x |
|
IRIX
IRIDEX
|
51.25% | 1.717 | 9.47% | 0.73x |
|
MYO
Myomo
|
-- | 2.090 | -- | 2.82x |
|
STXS
Stereotaxis
|
-- | 1.683 | -- | 0.74x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VMD
Viemed Healthcare
|
$36.1M | $5.3M | 8.76% | 9.21% | 10.63% | $3.2M |
|
AXGN
Axogen
|
$37.6M | $2M | -6.89% | -10.21% | 4.56% | $7.9M |
|
ELMD
Electromed
|
$12.6M | $2.5M | 15.91% | 15.91% | 15.64% | $2.9M |
|
IRIX
IRIDEX
|
$4.3M | -$1.9M | -146.36% | -157.91% | -16.15% | -$3.1M |
|
MYO
Myomo
|
$8.6M | -$245.3K | -48.64% | -48.64% | -2.03% | $2.5M |
|
STXS
Stereotaxis
|
$3.2M | -$7.6M | -139.2% | -139.2% | -120.3% | $1.3M |
Viemed Healthcare vs. Competitors
-
Which has Higher Returns VMD or AXGN?
Axogen has a net margin of 7.11% compared to Viemed Healthcare's net margin of 0.91%. Viemed Healthcare's return on equity of 9.21% beat Axogen's return on equity of -10.21%.
Company Gross Margin Earnings Per Share Invested Capital VMDViemed Healthcare59.54% $0.10 $137.3M AXGNAxogen76.06% $0.01 $151.4M -
What do Analysts Say About VMD or AXGN?
Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 94.15%. On the other hand Axogen has an analysts' consensus of $25.71 which suggests that it could grow by 61.83%. Given that Viemed Healthcare has higher upside potential than Axogen, analysts believe Viemed Healthcare is more attractive than Axogen.
Company Buy Ratings Hold Ratings Sell Ratings VMDViemed Healthcare3 0 0 AXGNAxogen5 0 0 -
Is VMD or AXGN More Risky?
Viemed Healthcare has a beta of 1.636, which suggesting that the stock is 63.604% more volatile than S&P 500. In comparison Axogen has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.462%.
-
Which is a Better Dividend Stock VMD or AXGN?
Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VMD or AXGN?
Viemed Healthcare quarterly revenues are $60.7M, which are larger than Axogen quarterly revenues of $49.4M. Viemed Healthcare's net income of $4.3M is higher than Axogen's net income of $450K. Notably, Viemed Healthcare's price-to-earnings ratio is 23.61x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.20x versus 3.75x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VMDViemed Healthcare1.20x 23.61x $60.7M $4.3M AXGNAxogen3.75x -- $49.4M $450K
-
Which has Higher Returns VMD or ELMD?
Electromed has a net margin of 7.11% compared to Viemed Healthcare's net margin of 12.11%. Viemed Healthcare's return on equity of 9.21% beat Electromed's return on equity of 15.91%.
Company Gross Margin Earnings Per Share Invested Capital VMDViemed Healthcare59.54% $0.10 $137.3M ELMDElectromed77.68% $0.22 $43.6M -
What do Analysts Say About VMD or ELMD?
Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 94.15%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 64.23%. Given that Viemed Healthcare has higher upside potential than Electromed, analysts believe Viemed Healthcare is more attractive than Electromed.
Company Buy Ratings Hold Ratings Sell Ratings VMDViemed Healthcare3 0 0 ELMDElectromed2 0 0 -
Is VMD or ELMD More Risky?
Viemed Healthcare has a beta of 1.636, which suggesting that the stock is 63.604% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.
-
Which is a Better Dividend Stock VMD or ELMD?
Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VMD or ELMD?
Viemed Healthcare quarterly revenues are $60.7M, which are larger than Electromed quarterly revenues of $16.3M. Viemed Healthcare's net income of $4.3M is higher than Electromed's net income of $2M. Notably, Viemed Healthcare's price-to-earnings ratio is 23.61x while Electromed's PE ratio is 30.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.20x versus 3.38x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VMDViemed Healthcare1.20x 23.61x $60.7M $4.3M ELMDElectromed3.38x 30.04x $16.3M $2M
-
Which has Higher Returns VMD or IRIX?
IRIDEX has a net margin of 7.11% compared to Viemed Healthcare's net margin of -16.69%. Viemed Healthcare's return on equity of 9.21% beat IRIDEX's return on equity of -157.91%.
Company Gross Margin Earnings Per Share Invested Capital VMDViemed Healthcare59.54% $0.10 $137.3M IRIXIRIDEX37.33% -$0.12 $5.4M -
What do Analysts Say About VMD or IRIX?
Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 94.15%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 112.2%. Given that IRIDEX has higher upside potential than Viemed Healthcare, analysts believe IRIDEX is more attractive than Viemed Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings VMDViemed Healthcare3 0 0 IRIXIRIDEX0 0 0 -
Is VMD or IRIX More Risky?
Viemed Healthcare has a beta of 1.636, which suggesting that the stock is 63.604% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.
-
Which is a Better Dividend Stock VMD or IRIX?
Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VMD or IRIX?
Viemed Healthcare quarterly revenues are $60.7M, which are larger than IRIDEX quarterly revenues of $11.6M. Viemed Healthcare's net income of $4.3M is higher than IRIDEX's net income of -$1.9M. Notably, Viemed Healthcare's price-to-earnings ratio is 23.61x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.20x versus 0.32x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VMDViemed Healthcare1.20x 23.61x $60.7M $4.3M IRIXIRIDEX0.32x -- $11.6M -$1.9M
-
Which has Higher Returns VMD or MYO?
Myomo has a net margin of 7.11% compared to Viemed Healthcare's net margin of -2.16%. Viemed Healthcare's return on equity of 9.21% beat Myomo's return on equity of -48.64%.
Company Gross Margin Earnings Per Share Invested Capital VMDViemed Healthcare59.54% $0.10 $137.3M MYOMyomo71.39% -$0.01 $24.7M -
What do Analysts Say About VMD or MYO?
Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 94.15%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 108.8%. Given that Myomo has higher upside potential than Viemed Healthcare, analysts believe Myomo is more attractive than Viemed Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings VMDViemed Healthcare3 0 0 MYOMyomo3 0 0 -
Is VMD or MYO More Risky?
Viemed Healthcare has a beta of 1.636, which suggesting that the stock is 63.604% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.
-
Which is a Better Dividend Stock VMD or MYO?
Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VMD or MYO?
Viemed Healthcare quarterly revenues are $60.7M, which are larger than Myomo quarterly revenues of $12.1M. Viemed Healthcare's net income of $4.3M is higher than Myomo's net income of -$260.1K. Notably, Viemed Healthcare's price-to-earnings ratio is 23.61x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.20x versus 5.14x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VMDViemed Healthcare1.20x 23.61x $60.7M $4.3M MYOMyomo5.14x -- $12.1M -$260.1K
-
Which has Higher Returns VMD or STXS?
Stereotaxis has a net margin of 7.11% compared to Viemed Healthcare's net margin of -118.53%. Viemed Healthcare's return on equity of 9.21% beat Stereotaxis's return on equity of -139.2%.
Company Gross Margin Earnings Per Share Invested Capital VMDViemed Healthcare59.54% $0.10 $137.3M STXSStereotaxis50.73% -$0.09 $11.4M -
What do Analysts Say About VMD or STXS?
Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 94.15%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 171.08%. Given that Stereotaxis has higher upside potential than Viemed Healthcare, analysts believe Stereotaxis is more attractive than Viemed Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings VMDViemed Healthcare3 0 0 STXSStereotaxis2 0 0 -
Is VMD or STXS More Risky?
Viemed Healthcare has a beta of 1.636, which suggesting that the stock is 63.604% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.
-
Which is a Better Dividend Stock VMD or STXS?
Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VMD or STXS?
Viemed Healthcare quarterly revenues are $60.7M, which are larger than Stereotaxis quarterly revenues of $6.3M. Viemed Healthcare's net income of $4.3M is higher than Stereotaxis's net income of -$7.5M. Notably, Viemed Healthcare's price-to-earnings ratio is 23.61x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.20x versus 5.25x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VMDViemed Healthcare1.20x 23.61x $60.7M $4.3M STXSStereotaxis5.25x -- $6.3M -$7.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
